GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyper Corporation Inc (XKRX:065650) » Definitions » Notes Receivable

Hyper (XKRX:065650) Notes Receivable : ₩0 Mil (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Hyper Notes Receivable?

Hyper's Notes Receivable for the quarter that ended in Mar. 2024 was ₩0 Mil.


Hyper Notes Receivable Historical Data

The historical data trend for Hyper's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyper Notes Receivable Chart

Hyper Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hyper Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hyper Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Hyper Notes Receivable Related Terms

Thank you for viewing the detailed overview of Hyper's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyper (XKRX:065650) Business Description

Traded in Other Exchanges
N/A
Address
Woolim A-1401, 583, Yangcheon-ro, Gangseo-gu, Seoul, KOR, 07547
Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Hyper (XKRX:065650) Headlines

No Headlines